Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry... Show more
Veeva Systems operates as a leading provider of industry cloud solutions for the global life sciences sector. Its fiscal year ends January 31, making the first quarter the three months ended April 30. The latest results follow a fiscal 2026 full year in which total revenue grew 16% to $3.195 billion. Investors closely monitor these quarterly updates for signs of sustained demand for Veeva’s Vault platform and related services amid evolving regulatory and digital transformation needs in pharmaceuticals and biotechnology.
Veeva announced fiscal 2027 first-quarter results on June 3, 2026. Total revenue reached $882.9 million, up 16% from $759.0 million in the year-ago quarter. Subscription revenue grew 15% to $730.2 million. GAAP operating income increased 17% to $273.1 million, while non-GAAP operating income rose 13% to $395.4 million. GAAP net income advanced 14% to $260.9 million, and non-GAAP net income grew 13% to $371.1 million. Diluted GAAP earnings per share were $1.57, compared with $1.37 a year earlier, and non-GAAP diluted earnings per share reached $2.24 versus $1.97 previously. The company noted that results exceeded guidance mainly due to stronger-than-expected revenue.
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. AI Screener
Following the June 3 release, investor focus centered on the beat relative to consensus estimates and the company’s forward guidance trajectory. The results reinforced confidence in Veeva’s growth trajectory within the life sciences cloud market, with particular attention paid to subscription revenue momentum and operating leverage.
Investors will track the company’s guidance for subsequent quarters and the full fiscal year to assess momentum in subscription services and any updates on new product adoption. Key areas include demand signals from biopharmaceutical customers, progress on Vault CRM implementations, and the contribution of AI-related offerings. Cost management, headcount trends, and margin expansion remain important watch points given the company’s emphasis on operating efficiency. Industry dynamics such as regulatory changes and digital transformation spending in life sciences could also influence results. The next earnings release is scheduled for late August 2026.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
a provider of industry-specific, cloud-based software solutions for the life sciences industry
Industry ServicestotheHealthIndustry